Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
15.19
Dollar change
-0.71
Percentage change
-4.47
%
Index- P/E- EPS (ttm)- Insider Own49.22% Shs Outstand26.65M Perf Week-0.20%
Market Cap374.74M Forward P/E- EPS next Y- Insider Trans10.32% Shs Float12.53M Perf Month-8.22%
Income- PEG- EPS next Q-0.70 Inst Own51.52% Short Float2.41% Perf Quarter37.97%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio3.04 Perf Half Y-
Book/sh-6.11 P/B- EPS next Y- ROA- Short Interest0.30M Perf Year-
Cash/sh1.44 P/C10.57 EPS next 5Y- ROE- 52W Range9.00 - 22.33 Perf YTD13.19%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-31.97% Beta-
Dividend TTM- Quick Ratio1.69 Sales past 5Y79.54% Gross Margin- 52W Low68.78% ATR (14)1.23
Dividend Ex-Date- Current Ratio1.69 EPS Y/Y TTM- Oper. Margin- RSI (14)45.32 Volatility7.09% 6.56%
Employees- Debt/Eq0.73 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price20.80
Option/ShortNo / Yes LT Debt/Eq0.43 EPS Q/Q-60.83% Payout- Rel Volume0.39 Prev Close15.90
Sales Surprise- EPS Surprise-1184.16% Sales Q/Q-100.00% EarningsDec 11 BMO Avg Volume99.08K Price15.19
SMA20-6.95% SMA50-0.58% SMA2007.50% Trades Volume38,427 Change-4.47%
Date Action Analyst Rating Change Price Target Change
Nov-28-23Initiated Stifel Buy $20
Nov-28-23Initiated RBC Capital Mkts Outperform $22
Nov-28-23Initiated Leerink Partners Outperform $19
Nov-28-23Initiated JP Morgan Overweight $20
Nov-28-23Initiated Chardan Capital Markets Buy $23
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longitude Capital Partners IV,10% OwnerNov 07Buy11.00454,5454,999,9952,567,100Nov 09 08:32 PM
Omega Fund VI, L.P.10% OwnerNov 07Buy11.00454,5454,999,9952,157,623Nov 09 08:36 PM
Lundbeckfond Invest A/S10% OwnerNov 07Buy11.00227,2722,499,9921,835,959Nov 09 08:33 PM